Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment

Basit Öğe Kaydı
dc.authoridOnen Goktepe, Serife Sebnem/0000-0002-6772-237X
dc.authoridozdemir karadas, nihal/0000-0002-0019-7347
dc.authorscopusid53163863600
dc.authorscopusid57972232600
dc.authorscopusid57226609173
dc.authorscopusid55575208300
dc.authorscopusid57203864701
dc.authorscopusid56021764600
dc.authorscopusid35885183600
dc.contributor.authorKaradas, Nihal
dc.contributor.authorGoktepe, Serife Sebnem Onen
dc.contributor.authorBas, Ilke
dc.contributor.authorEce, Dilek
dc.contributor.authorOzdemir, Hamiyet Hekimci
dc.contributor.authorBalkan, Can
dc.contributor.authorKavakli, Kaan
dc.date.accessioned2023-01-12T19:51:30Z
dc.date.available2023-01-12T19:51:30Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractChronic myeloid leukemia (CML) is very rare during childhood. Tyrosine kinase inhibitors (TKI) provide very good results in terms of survival. The medical records of 15 chronic phase (CP)-CML patients in a university hospital pediatric hematology department between 1997 and 2022 were reviewed retrospectively. Complete hematological response was documented in all patients between 20 and 68 (median 30) days of treatment. Major molecular response was achieved in seven patients within 6 months. Median follow-up for the study group was 79 (range 3-330) months and overall survival was 100%. Three patients (2 blastic transformation, 1 therapy resistant) underwent bone marrow transplantation (BMT) and one with blastic transformation is scheduled to undergo BMT. TKI were discontinued in three patients after a median of 86 (range 73-177) months. The complete molecular remission maintenance period before discontinuation of TKI was 81 (range 62-122) months. While no molecular relapse was seen before the last follow-up, the median overall follow-up period was 152 (range 131-300) months. In conclusion, recent advances have led to a very good prognosis for children with CP-CML. With TKI treatment, most patients continue their lives without disease progression. Additionally, in selected patients TKI can be discontinued without molecular relapse.en_US
dc.identifier.doi10.1007/s12185-022-03497-4
dc.identifier.issn0925-5710
dc.identifier.issn1865-3774
dc.identifier.pmid36401784en_US
dc.identifier.scopus2-s2.0-85142292855en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1007/s12185-022-03497-4
dc.identifier.urihttps://hdl.handle.net/11454/76284
dc.identifier.wosWOS:000886323500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofInternational Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectPediatricsen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectImatinib Cessationen_US
dc.subjectSurvivalen_US
dc.subjectChildrenen_US
dc.subjectRecommendationsen_US
dc.subjectRemissionen_US
dc.subjectCmlen_US
dc.titleCurrent childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu